登录

中国糖尿病研究人员证明早期胰岛素治疗对心血管健康有显著益处

Diabetes Researchers in China Demonstrate Early Insulin Therapy Significant Benefits Cardiovascular Health

BioSpace 2024-06-19 18:39 翻译由动脉网AI生成,点击反馈

可切换为仅中文


BEIJING, June 19, 2024 /PRNewswire/ -- Recently, Professor Jianping Weng of the University of Science and Technology of China (USTC) and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their latest research on the effects of early insulin therapy on cardiovascular health in adults with Type 2 Diabetes Mellitus (T2DM) in the journal Signal Transduction and Targeted Therapy.

北京,2024年6月19日/新华社/--最近,中国科技大学(USTC)教授、安徽医科大学校长翁建平教授及其来自USTC、南方医科大学和北京大学的研究团队在《信号转导与靶向治疗》杂志上发表了他们关于早期胰岛素治疗对2型糖尿病(T2DM)成人心血管健康影响的最新研究结果。

This study is the first in the world to demonstrate that early insulin therapy is associated with a significant reduction in the incidence of cardiovascular events in newly diagnosed patients with T2DM..

。。

This research signifies a breakthrough in the field of diabetes treatment, compelling us to rethink the diabetes treatment model.

这项研究标志着糖尿病治疗领域的突破,迫使我们重新思考糖尿病治疗模式。

Diabetes has remained a serious global public health issue for over a century, with its burden only growing as populations shift to more urban, sedentary ways of living. The heightened blood glucose levels of a person with diabetes can damage their cardiovascular systems, placing them at increased risk of cardiovascular events, which is why cardiovascular disease is one of the leading causes of mortality among people with diabetes.

一个多世纪以来,糖尿病一直是一个严重的全球公共卫生问题,随着人口转向更城市化、久坐不动的生活方式,糖尿病的负担只会增加。。

As such, effective blood glucose control, which has always been the main goal of diabetes therapy, is important to reduce the risk of cardiovascular events..

因此,有效的血糖控制一直是糖尿病治疗的主要目标,对于降低心血管事件的风险很重要。。

Professor Weng and his led observed a total of 5,424 patients with type 2 diabetes over a period of 24 years. The results showed that, compared with patients who did not receive early insulin therapy, those who did saw a 31% reduced incidence of stroke and 28% reduction in hospitalization for heart failure, though it found no significant difference in the risk of coronary heart disease.

翁教授和他的领导在24年的时间里共观察到5424名2型糖尿病患者。结果显示,与未接受早期胰岛素治疗的患者相比,那些接受早期胰岛素治疗的患者中风发生率降低了31%,心力衰竭住院率降低了28%,但冠心病风险没有显着差异。

This discovery stands to change the way doctors and patients approach therapy options for new diagnoses of TD2M, as the significant cardiovascular benefits may lead more favoring early insulin adoption at a time when many first explore alternatives to insulin therapy..

这一发现将改变医生和患者对TD2M新诊断的治疗选择方式,因为在许多人首次探索胰岛素治疗替代方案的时候,显着的心血管益处可能会导致更倾向于早期采用胰岛素。。

Over two decades of research by Professor Weng supports early insulin therapy

翁教授20多年的研究支持早期胰岛素治疗

The traditional model for treating newly diagnosed T2DM is a conservative 'step-by-step' method that typically begins with lifestyle changes such as diet and exercise, with physicians only recommending pharmaceutical intervention such as insulin once the disease has progressed and it is becoming clear that blood glucose levels are going uncontrolled.

治疗新诊断的T2DM的传统模式是一种保守的“循序渐进”方法,通常从饮食和运动等生活方式的改变开始,医生只建议在疾病进展后进行药物干预,如胰岛素,血糖水平正在失控。

This can be a problematic approach, as this often means that patients go months, even years, with high blood glucose levels causing lasting internal damage and increasing risk of complications. After years of clinical experience struggling with this contradiction, in 2000 Chinese endocrinologists Jianping Weng and Linong Ji began formally exploring the effects of early insulin therapy on patient outcomes.

这可能是一种有问题的方法,因为这通常意味着患者数月甚至数年的高血糖水平会导致持续的内部损伤并增加并发症的风险。经过多年的临床经验与这一矛盾的斗争,2000年,中国内分泌学家翁建平和季立农开始正式探索早期胰岛素治疗对患者预后的影响。

Initial results proved promising, as early insulin therapy demonstrated an improvement in pancreatic islet secretion and reduced complications from diabetes. This study proved that, with the right therapy, T2DM could be reversed and thus became an important basis for the formulation of diabetes guidelines in many countries..

最初的结果证明是有希望的,因为早期胰岛素治疗显示出胰岛分泌的改善和糖尿病并发症的减少。这项研究证明,通过正确的治疗,T2DM可以逆转,从而成为许多国家制定糖尿病指南的重要基础。。

In 2001, Weng and Ji also coincidentally discovered that insulin intensification in type 2 diabetes can delay the progressive failure of beta cells. Subsequent observational studies by Weng's team showed that short-term intensive insulin treatment in patients with newly diagnosed T2DM and people with severe hyperglycemia could induce long-term improvements in blood glucose control and beta cell function.

2001年,翁和季也巧合地发现,2型糖尿病的胰岛素强化可以延缓β细胞的进行性衰竭。翁的团队随后进行的观察性研究表明,对新诊断的T2DM患者和严重高血糖患者进行短期强化胰岛素治疗可以长期改善血糖控制和β细胞功能。

These research results were published in Diabetes Care in 2004..

这些研究结果发表在2004年的《糖尿病护理》杂志上。。

Weng's team then conducted a multi-center randomized controlled study demonstrating that early insulin therapy was superior to oral blood glucose drugs in restoring and maintaining beta cell function and lowering overall blood glucose levels. These results were published in The Lancet in 2008, marking the first time such a 'honeymoon period' induced by early insulin therapy was mentioned in the prestigious publication.

翁的团队随后进行了一项多中心随机对照研究,证明早期胰岛素治疗在恢复和维持β细胞功能以及降低总体血糖水平方面优于口服血糖药物。这些结果发表在2008年的《柳叶刀》上,标志着这本权威刊物首次提到早期胰岛素治疗引起的“蜜月期”。

Weng and his team was the first to prove that pancreatic islet function in T2M is reversible, and successfully verified the 'beta cell rest' theory in T2DM therapy..

翁和他的团队是第一个证明T2M中胰岛功能是可逆的,并成功验证了T2DM治疗中的“β细胞休息”理论。。

Professor Weng said, 'Clinical results show that early insulin therapy can not only successfully control blood glucose and reduce overall blood sugar levels, but also restore beta cell function and reduce insulin resistance. This new treatment method encourages us to rethink how we approach diabetes treatment and significantly impact how we formulate treatment strategies.' Initially proposed to answer the question as to when physicians should recommend starting insulin treatment, Weng's research is still often cited by endocrinologists around the world, with Dutch journal Elsevier rating him as one of China's most cited scholars for three consecutive years from 2020 to 2022.

翁教授说:“临床结果表明,早期胰岛素治疗不仅可以成功控制血糖并降低总体血糖水平,还可以恢复β细胞功能并降低胰岛素抵抗。这种新的治疗方法鼓励我们重新思考如何治疗糖尿病,并对我们制定治疗策略产生重大影响。”最初被提议回答医生应该何时建议开始胰岛素治疗的问题,翁的研究仍然经常被世界各地的内分泌学家引用,荷兰期刊Elsevier连续三年将他评为2020年至2022年中国被引用最多的学者之一。

The results of his studies on early insulin therapy have been cited by more than 60 treatment guidelines around the world, including 'Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy' which was jointly published by American Diabetes Association and the European Diabetes Association in 2009 and the 2013, 2017, and 2020 editions of China's Type 2 Diabetes Prevention and Treatment Guidelines.

他对早期胰岛素治疗的研究结果已被全球60多个治疗指南引用,其中包括“2型糖尿病高血糖的医学管理:治疗开始和调整的共识算法”,该算法由美国糖尿病协会和欧洲糖尿病协会于2009年联合发布,以及2013年、2017年和2020年版的中国2型糖尿病预防和治疗指南。

The paper has also been included or cited in many endocrinology textbooks..

这篇论文也被许多内分泌学教科书收录或引用。。

The cardiovascular benefits of early insulin therapy in people newly diagnosed with T2DM

早期胰岛素治疗对新诊断T2DM患者的心血管益处

For most people with T2DM, insulin therapy is eventually necessary in order to control blood glucose levels. Previous studies demonstrated that early insulin therapy can help control blood control and restore beta cell function in patients with type 2 diabetes, but how this therapy affected cardiovascular health has remained a mystery..

对于大多数T2DM患者来说,为了控制血糖水平,胰岛素治疗最终是必要的。先前的研究表明,早期胰岛素治疗可以帮助控制2型糖尿病患者的血液控制并恢复β细胞功能,但这种治疗如何影响心血管健康仍然是一个谜。。

This recently published study into how early insulin therapy can reduce the incidence of cardiovascular events such as stroke, heart failure, and coronary heart disease in newly diagnosed patients with T2DM can be seen as a follow-up to Weng's 2008 article in The Lancet in that it demonstrates even further benefits from early insulin therapy on long-term patient outcomes.

这项最近发表的关于早期胰岛素治疗如何降低新诊断的T2DM患者中风,心力衰竭和冠心病等心血管事件发生率的研究可以看作是翁2008年在《柳叶刀》上发表的文章的后续研究,因为它证明了早期胰岛素治疗对长期患者预后的进一步益处。

This new evidence promoting early insulin therapy could change the future of insulin therapy and provide key evidence for setting treatment guidelines..

这一促进早期胰岛素治疗的新证据可能会改变胰岛素治疗的未来,并为制定治疗指南提供关键证据。。

Speaking on the results of this study, Professor Ji said, 'Type 2 diabetes is an important risk factor for cardiovascular disease morbidity and mortality. Clinical guidelines also emphasize that, when selecting a potential therapy, in addition to lowering blood glucose levels, it is also very important to reduce the risk of cardiovascular events.

在谈到这项研究的结果时,季教授说,“2型糖尿病是心血管疾病发病率和死亡率的重要危险因素。临床指南还强调,在选择潜在疗法时,除了降低血糖水平外,降低心血管事件的风险也非常重要。

Different patients should adopt individualized target management, blood sugar monitoring and corresponding treatment plans. We hope that this study will provide a basis for exploring more effective ways to reduce the risk of cardiovascular disease in patients with diabetes.'.

不同患者应采取个体化的目标管理、血糖监测和相应的治疗方案。我们希望这项研究将为探索降低糖尿病患者心血管疾病风险的更有效方法提供基础。”。

Early insulin therapy may bring cardiovascular benefits by improving blood glucose control in patients with type 2 diabetes, producing metabolic memory, reducing glucotoxicity, promoting the dedifferentiation of beta cells, improving beta cell function, and reducing the production of pro-inflammatory cytokines..

早期胰岛素治疗可能通过改善2型糖尿病患者的血糖控制,产生代谢记忆,降低糖毒性,促进β细胞去分化,改善β细胞功能和减少促炎细胞因子的产生而带来心血管益处。。

As research continues and treatment methods improve, studies such as this challenge us to rethink current diabetes treatment models and correct misconceptions about the use of insulin. With better treatment, newly diagnosed people with diabetes will be able to reduce complications and the long-term impact of their condition, helping them live longer and healthier lives..

随着研究的继续和治疗方法的改进,类似这样的研究挑战我们重新思考当前的糖尿病治疗模式,并纠正对胰岛素使用的误解。通过更好的治疗,新诊断的糖尿病患者将能够减少并发症和病情的长期影响,帮助他们活得更长更健康。。

View original content:https://www.prnewswire.com/news-releases/diabetes-researchers-in-china-demonstrate-early-insulin-therapy-significant-benefits-cardiovascular-health-302176724.html

查看原始内容:https://www.prnewswire.com/news-releases/diabetes-researchers-in-china-demonstrate-early-insulin-therapy-significant-benefits-cardiovascular-health-302176724.html

SOURCE Anhui Medical University

来源安徽医科大学

推荐阅读

120多名医生参加了关于介入骨科和非手术治疗进展的会议

Medgate Today 2024-07-13 20:52

北京大学第三医院4个牵头项目荣获2023年北京医学科技奖

北京大学医学部 2024-07-13 20:23

与NeoRAS野生型转移性癌症相关的临床特征——SCRUM-Japan GOZILA亚研究

Nature 2024-07-13 19:13

BioSpace

3630篇

最近内容 查看更多

医疗生物技术公司CellProthera和BioCardia合作ProtheraCytes™治疗急性心肌梗死的II期试验取得成功

2024-07-09

肿瘤药物研发商iTeos完成GALAXIES Lung-301 3期研究首位患者给药

2024-07-09

Theralase(R)完成了775000加元的第一批非破产私募

2024-07-08

产业链接查看更多